Invesco
JNCE

Invesco’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Invesco’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-10,319
Closed -$11.5K – 4047
2022
Q4 		$11.5K Sell
10,319
-183,177
-95% -$261K ﹤0.01% 3997
2022
Q3 		$452K Buy
193,496
+3,323
+2% +$11.8K ﹤0.01% 3297
2022
Q2 		$576K Buy
190,173
+179,406
+1,666% +$873K ﹤0.01% 3261
2022
Q1 		$73K Buy
10,767
+579
+6% +$4.13K ﹤0.01% 3895
2021
Q4 		$86K Sell
10,188
-2,330
-19% -$19.2K ﹤0.01% 3922
2021
Q3 		$93K Buy
12,518
+1,370
+12% +$8.49K ﹤0.01% 3952
2021
Q2 		$76K Buy
+11,148
New +$92.6K ﹤0.01% 3924
2021
Q1 		– Sell
-12,792
Closed -$89K – 3972
2020
Q4 		$89K Sell
12,792
-76,120
-86% -$592K ﹤0.01% 3656
2020
Q3 		$726K Sell
88,912
-141,380
-61% -$877K ﹤0.01% 2958
2020
Q2 		$1.59M Buy
+230,292
New +$1.24M ﹤0.01% 2584
2020
Q1 		– Sell
-117,169
Closed -$1.02M – 3753
2019
Q4 		$1.02M Buy
+117,169
New +$633K ﹤0.01% 2988

Other funds holding JNCE

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
ACM
Ardent Capital Management Cincinnati, Ohio $241M AUM 23.63% 1-Year Est. Return

Invesco's JNCE Position: Q1 2023 in Review

Invesco sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2023, closing a stake of 10,319 shares — an estimated $11.5K sold.

Invesco first reported a position in JNCE in Q4 2019 and held it in 11 quarters. The position peaked at $1.59M in Q2 2020. 84 funds tracked by Wall St. Rank hold JNCE as of Q1 2023.

  • Invesco reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Invesco sold 10,319 Jounce Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $11.5K.
  • Invesco first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2019 and held it in 11 quarters.
  • Invesco's Jounce Therapeutics, Inc. Common Stock position peaked at $1.59M in Q2 2020.
  • 84 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Invesco's 13F filing for Q1 2023, filed 12 May 2023.